14

[]

E. The second

CLAIMS

- 1. An antibiotic composition comprising at least 50% by weight of Erythromycin B (or a pharmaceutically acceptable derivative thereof) based on the total weight of antibiotic present in the composition.
- 2. An antibiotic composition as claimed in claim 1 which contains at least 75% by weight of Erythromycin B (or a pharmaceutically acceptable derivative thereof) based on the total weight of antibiotic present in the composition.
- 3. An antibiotic composition as claimed in claim 2 which contains at least 90% by weight of Erythromycin B (or a pharmaceutically acceptable derivative thereof) based on the total weight of antibiotic present in the composition.
- 4. An antibiotic composition as claimed in claim 3-which contains Erythromycin B (or a pharmaceutically acceptable derivative thereof) as substantially the only antibiotic.
- 5. An antibiotic composition as claimed in any one of claims 1 to 4 which contains 50mg to 1g of Erythromycin B (or a pharmaceutically acceptable derivative thereof).
- 6. An antibiotic composition as claimed in claim 5 which contains 100mg to 500mg of Erythromycin B (or a pharmaceutically acceptable derivative thereof).
- 7. An antibiotic composition as claimed in any one of claims 1 to 6 in the form of a tablet, a capsule, a suspension, an elixir, a syrup or an injectable.
- 8. An antibiotic composition as claimed in claim 7 in the form of a tablet containing 250mg to 500mg of Erythromycin B (or a pharmaceutically acceptable derivative thereof).

- 8. An antibiotic composition as claimed in claim 7 in the form of a tablet containing 250mg to 500mg of Erythromysin B (or a pharmaceutically acceptable derivative thereof).
- pharmaceutically acceptable derivative of Erythromycin B and where said derivative is a 2'ester of Erythromycin B or Erythromycin B and ether.
- 10. A 2'-ester of Erythromycin B or of Erythromycin B enol ether.
- 11. An ester as claimed in claim 10 wherein the ester is a carboxylate ester of a mono or dicarboxylic acid.
- 12. An ester as claimed in claim 12 which is a succinate ester.
- 13. An antibiotic composition comprising a therapeutically effective amount of an ester as claimed in any one of claims 10 to 12.
- The use of Erythromycin B (or a pharmaceutically acceptable derivative thereof) for the manufacture of a pharmaceutical composition for the treatment of microbial infection.
- 15. A method of treating a microbial infection comprising administering to a patient in need of such treatment a therapeutically effective amount of Erythromycin B (or a pharmaceutically acceptable derivative thereof).
- 16. Erythromycin B (or a pharmaceutically acceptable derivative thereof) for use in therapeutic administration for the treatment of microbial infection.
- A use or method as claimed in any one of claims 13, 14 or 15 in which the microbial infection is TB, Syphilis, Helicobacter pylori, or Chlamydia.